Neurology
Salanersen Phase 1b Data Show New Motor Milestones in SMA Children Previously Treated with Gene Therapy
New phase 1b data show Salanersen, a once-yearly ASO, improved motor function in SMA children who had prior gene therapy. Biogen launches phase 3 program.




























